Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 2, 2008, Pages 168-173

  Yilmaz, Aylin ^a,d   Price, Richard W ^b   Spudich, Serena ^b   Fuchs, Dietmar ^c   Hagberg, Lars ^a   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretroviral therapy; Cerebrospinal fluid; HIV 1 RNA; Neopterin

Indexed keywords

ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEOPTERIN; NEVIRAPINE; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BLOOD; CEREBROSPINAL FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; NEOPTERIN; RADIOIMMUNOASSAY; RNA, VIRAL; VIRAL LOAD;

EID: 38649086733     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815ace97     Document Type: Article

References (33)

1. Wirleitner B, Schroecksnadel K, Winkler C, et al. Neopterin in HIV-1 infection. Mol Immunol. 2005;42:183-194.
2. Furukawa Y, Nishi K, Kondo T, et al. Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci. 1992;111:65-72.
3. Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand. 1987;75:352-355.
4. Hagberg L, Dotevall L, Norkrans G, et al. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis. 1993;168:1285-1288.
5. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferongamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41:69-74.
6. Abdulle S, Hagberg L, Svennerholm B, et al. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS. 2002;16:2145-2149.
7. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:320-328.
8. Mellgren Å, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther. 2005;10:701-707.
9. Spudich S, Lollo N, Liegler T, et al. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194:1686-1696.
10. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS. 1993;7:1581-1587.
11. Haas D, Stone J, Clough LA, et al. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther. 2000;68:367-374.
12. Haworth SJ, Christofalo B, Anderson RD, et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr. 1998;17:235-238.
13. Yilmaz A, Ståhle L, Hagberg L, et al. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis. 2004;36:823-828.
14. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005;41:1787-1793.
15. Yilmaz A, Svennerholm B, Hagberg L, et al. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther. 2006;11:833-837.
16. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
17. Werner E, Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clin Chem. 1987;33:62-66.
18. Mayersbach P, Augustin R, Schennach H, et al. Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin Chem. 1994;40:265-266.
19. Hagberg L, Andersson L, Abdulle S, et al. Clinical application of cerebrospinal fluid neopterin concentrations in HIV infection. Pteridines. 2004;15:102-106.
20. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/ acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10:350-357.
21. Gisslén M, Ahlqvist-Rastad J, Albert J, et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scand J Infect Dis. 2006;38:86-103.
22. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843.
23. Gisslén M, Svennerholm B, Norkrans G, et al. Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis. 2000;32:365-369.
24. Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54:927-936.
25. Gisslén M, Fuchs D, Svennerholm B, et al. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21:271-276.
26. Aquaro S, Perno CF, Balestra E, et al. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol. 1997;62:138-143.
27. Gisslén M, Norkrans G, Svennerholm B, et al. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175:434-437.
28. Portegies P, de Gans J, Lange JM, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ. 1989;299:819-821.
29. Hagberg L, Norkrans G, Gisslén M, et al. Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine. Scand J Infect Dis. 1996;28:329-333.
30. Gisolf EH, Enting RH, Jurriaans S, et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/ stavudine. AIDS. 2000;14:1583-1589.
31. Lafeuillade A, Solas C, Halfon P, et al. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials. 2002;3:27-35.
32. Yeh R, Letendre S, Novak I, et al. Single agent therapy with lopinavir/ ritonavir controls HIV-1 replication in the central nervous system [abstract 381]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
33. Harrington PR, Haas DW, Ritola K, et al. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol. 2005;79:7959-7966.